Clinical TrialID 2543

Phenoxodiol in Treating Patients With Refractory Solid Tumors

NCT00022295

Unspecified Adult Solid Tumor, Protocol Specific

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
2543
Evidence Id
2543
Core Evidence Id
2543
Source Clinical Trial Id
2522
Herb2 Clinical Trial Id
HBCT002522
Nct Id
NCT00022295
Title
Phenoxodiol in Treating Patients With Refractory Solid Tumors
Status
Completed
Phase
Phase 1
Study Result
No
Study Condition
Unspecified Adult Solid Tumor, Protocol Specific
Study Type
Interventional
Study Design
Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT
Intervention
DRUG: idronoxil
Intervention Allocation
Intervention Model
Intervention Mask
Intervention Purpose
Treatment
Gender
All
Age
Adult, Older_Adult
Enrollment
36
Outcome Measure
Sponsor Collaborator
Kazia Therapeutics Limited
Funded By
INDUSTRY
Location
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, 44195, United States
Other Id
CDR0000068802|NOVOGEN-NV06-0024|CCF-4269|NCI-V01-1663
Start Date
2001-08
Primary Completion Date
Completion Date
2007-10
First Posted
2003-01-27
Results First Posted
Last Update Posted
2013-03-26
Study Document
Study Url
https://clinicaltrials.gov/study/NCT00022295
Title Cn
Title En
Phenoxodiol in Treating Patients With Refractory Solid Tumors
Bilingual Status
semi_complete